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scheduled control in 41/45 patients. At all scheduled controls shrinkage was statistically
significant. The mean size of 41 lesions evaluated at presentation, one, six and twelve
months follow up was 34.12 mm (9-80, SD15.52), 29.93 mm (6-70, SD14.86), 29.10
mm (6-70, SD14.96) and 26.88 (6-63, SD15.39) respectively. Diameter reduction rate
was 15.5%, 3.8% and 11% at 1, 6 and 12 months (statistically significant: p0.05).
Presence of mural thrombus did not influence shrinkage timing (p0.05), while complex
lesion anatomy (presence of side branches) delay shrinkage (p0.05).
Conclusions: data at one year FU show that CMPS is an effective device for repair of
PAA and VAA with/without collateral branches, with significant shrinkage of the sac,
allowing a broader group of patients to be treated with endovascular repair with results
comparable to other traditional endovascular technique.
TCT-6
Biodegradable polymer-based Biolimus A9-eluting stent for the treatment of
infrapopliteal arteries in critical limb ischemia: long-term clinical and
angiographic follow-up.
Eugenio Stabile1, Luigi Salemme1, Giovanni Sorropago1, Angelo Cioppa1,
Vittorio Ambrosini1, Grigore Popusoi1, Armando Pucciarelli1, Linda Cota1,
Tullio Tesorio1, Paolo Rubino1
1Clinica Montevergine, Mercogliano, Italy
Background: To present angiographic and clinical results of a retrospective registry
assessing the performance of a biodegradable polymer-based Biolimus A9-eluting stent
(BES) in the treatment of focal below the knee atherosclerotic disease.
Methods: From 05/2009 to 05/2011, 25 patients (17 men; mean age 71.8  6.7 years)
with chronic lower limb ischemia (Rutherford categories 3-6) underwent primary BES
placement in focal infrapopliteal lesions. Dual antiplatelet theraphy (DAPT) was pre-
scribed for six month. The primary endpoint was freedom from angiographic in-stent
stenosis (ISRS) 50%. Clinical endpoints were death, amputation, and bypass surgery.
Results were correlated with patient and lesion characteristics and cumulative outcomes
were assessed with Kaplan-Meier analysis.
Results: Technical success was achieved in all cases. Freedom from ISRS were 100 %
after 6 months, 96.0% after 12 months, and 92.0% at 12 months. No stent occlusions
occurred. During clinical follow-up of 25 patients over a mean 14 6 months, there were
no deaths, no mayor amputations, and no need for bypass surgery. Clinical status
improved in all the patients.
Conclusions: Treatment of focal infrapopliteal lesions with BES showed encouraging
angiographic results in this registry. Clinical improvement was robust and particualry
evident in CLI patients. Six months of DAPT were sufficient to prevent stent thrombosis.
Further studies are needed to evaluate the potential clinical benefit of BES as compared
to balloon angioplasty or bare metal stents in the treatment of infrapopliteal lesions.
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Plaque Excision as a Treatment Option for Critical Limb Ischemia: 1-Year
Results of the DEFINITIVE LE Study
James McKinsey1, Thomas Zeller2, Lawrence Garcia3
1Columbia/Cornell New York Presbyterian Hospital System, New York, NY,
2Universitaets-Herzzentrum Freiburg-Bad Krozingen, Bad Kronzingen, Germany,
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Background: The endovascular treatment of patients with critical limb ischemia (CLI)
is complex and poorly studied. Plaque excision allows the debulking of the atherosclerotic
plaque without the need of leaving a foreign body behind. The DEFINITIVE LE study
was a global study that assessed the effectiveness of plaque excision using the Silver-
Hawk® and TurboHawkTM Systems (Covidien/ev3, Plymouth, MN) for PAD in
femoropopliteal and tibial-peroneal arteries with specific evaluation of patients with
claudication and CLI.
Methods: The DEFINITIVE LE study enrolled 200 patients (278 lesions) with CLI who
underwent revascularization with plaque excision. . Endpoints were assessed by indepen-
dent core laboratories. The primary endpoint for CLI patients was freedom from major
unplanned amputation of the target limb at 1 year.
Results: In 200 patients in the DEFINITIVE LE study with CLI, mean age was 72.1
years, 50% were male, and 69.0% had diabetes. Other frequent comorbidities included
hypertension (92.5%), hyperlipidemia (76.5%) and renal insufficiency (24.0%). The mean
lesion length was 7.1 cm and 24.5% of lesions were 10 cm. The mean baseline stenosis
was 75.8% and 36.8% of lesions were calcified. At 6 months and at 1 year, freedom from
amputation was 97.3% and 95.8%,. Primary patency was 86.9% at 6 months and 69.2%
at 1 year. Other secondary endpoints demonstrated significant, sustained improvements as
shown below.
Outcome Baseline
3-Month
Follow-Up
6-Month
Follow-Up
12-Month
Follow-Up
Rutherford Clinical
Category
RCC 4 37.00% n/a 2.10% 5.30%
RCC 5 53.00% n/a 21.00% 14.30%
RCC 6 10.00% n/a 5.60% 4.50%
Ankle-Brachial
Index
0.59 0.18 n/a 0.70 0.26 0.78 0.26
EQ-5D Score 0.64 0.22 n/a 0.74 0.21 0.74 0.21
EQ-5D Visual
Analog
60.2 20.8 n/a 68.3 19.2 70.2 18.1
Wound Healing
(Wagner scale)
0 1.80% 51.70% 62.40% 72.20%
1 54.60% 25.00% 28.60% 17.40%
2 19.60% 10.00% 3.00% 4.30%
3 6.10% 5.00% 1.50% 0.90%
4 16.00% 6.70% 4.50% 1.70%
5 1.80% 1.70% 0.00% 3.50%
Conclusions: Plaque excision for CLI results in high rates of limb salvage and good
primary patency at 1 year, as well as improvements in wound healing, clinical status as
measured by RCC and ABI, and improved quality of life for this challenging patient
population. This was accomplished with a very low rate of stent use which would allow
for future intervention with new technology that may be excluded if a stent were in place.
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Morphological assessment of renal arteries after radiofrequency catheter-
based sympathetic denervation in a porcine model
Michael Joner1, Kristin Steigerwald2, Karl-Ludwig Laugwitz3
1Deutsches Herzzentrum München, Munich, Germany, 2Deutsches Herzzentrum
München, Munich, Bavaria, 3Deutsches Herzzentrum München und 1. med. Klinik
TUM, Munich, Bavaria
Background: Catheter-based renal artery denervation has been successfully introduced
as alternative treatment for patients suffering from drug-resistant essential hypertension.
However, the local morphological changes within the vessel wall accompanying this
technique remain elusive and we sought to characterize these by utilizing the Simplicity®
(Medtronic Ardian, Mountain View, CA, USA) radiofrequency catheter approach.
Methods: Following treatment of seven pigs, renal arteries were assigned to either the
acute (n6), sub-acute (10-day follow-up, n6) or control (untreated, n2) group. At
follow-up blood analysis, final angiography and optical coherence tomography (OCT)-
imaging of the treated arteries were performed and renal arteries and kidneys were
processed for histopathology and immunohistochemistry.
Results: Radiofrequency derived energy application to the vessel wall induced transmu-
ral tissue coagulation and loss of endothelium resulting in local thrombus formation also
detectable by OCT. At 10 days, the luminal surface was almost completely re-
endothelialized. Mural wall damage was replaced by fibrotic tissue and the adventitial
layer showed strong inflammatory infiltration including vasculogenesis. Remnant auto-
nomic nerve fascicles within the lesion segments of the sub-acute group displayed
enhanced vacuolic degeneration and an impaired neurofilament protein immunostaining
pattern. Examination of the kidneys revealed no abnormalities and blood parameters
remained within the physiological range.
Conclusions: Catheter-based application of radiofrequency energy resulted in circum-
scribed transmural injury within the arterial wall affecting autonomic nerve fascicles in a
delayed manner. Acute loss of endothelialization resulted in thrombus formation leaving
kidney perfusion unimpaired.
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Efficacy of renal denervation is positively impacted by longitudinal treatments
Meital Mazor1
1VESSIX VASCULAR, Laguna Hills, CA
Background: Catheter-based percutaneous renal denervation (RDN) has shown durable
reductions of blood pressure in patients with uncontrolled hypertension. The importance
of applying circumferential denervations inside the renal arteries is known to contribute to
efficacy; however, the significance of denervations along the entire renal artery length is
yet to be appreciated.
Methods: We used the V2 System™ (Vessix Vascular Inc., Laguna Hills, CA) for the
renal denervation procedures. The V2 System consists of a proprietary bipolar RF
generator and an over-the-wire low pressure balloon catheter with an array of radiofre-
quency (RF) electrodes mounted on the exterior in an offset helical pattern. Each
temperature controlled dose (68°C) of bipolar energy is delivered for 30 seconds. A total
of 15 juvenile Yorkshire swine were treated bilaterally (n3 in each group, see table).
Efficacy was evaluated at 14 days post treatment using an HPLC-MS/MS method to
measure kidney tissue norepinephrine (NEPI). In addition, histopathologic methods were
used to assess the percentage of affected nerves.
Results: A single V2 treatment per artery with 95% circumferential coverage and 60%
length coverage (21 mm) was applied resulting in 40% of nerves being affected and a
NEPI reduction of 46% when compared to control group endogenous level. Increasing the
circumferential coverage by 35% did not change efficacy. However, increasing coverage
length by 40% significantly increased NEPI reduction to 78% and significantly increased
the percentage of affected nerves to 58% (p0.05) and was comparable to surgical
denervation.
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Single V2
treatment
One treatment per artery
(each electrode  4 mm
long and 2.5 mm wide)
95% 60% 322331 46% 40%11
V2 treatments
of full artery
length
Up to 2 treatments in
order to treat the entire
length of the artery
(proximal treatment
could be partial, with only
a few RF electrodes
activated)
95% 100% 132191 78% 58%17
Single V2
treatment
using balloon
with
horizontal RF
electrodes
Electrodes were
positioned in an
horizontal pattern in
order to increase
circumferential coverage
(each electrode is 2.5
mm long and 4 mm
wide)
130% 60% 356321 41% 37%14
Surgical
denervation
Adventitia was separated
along the entire length of
the artery and renal
nerves removed
100% 100% 154285 75% NA
Untreated
Sham control
Interventional procedure,
without renal denervation
treatment.
0% 0% 60161 0% 0%
Conclusions: Longitudinal denervations of the renal artery, in addition to circumferential
denervations during RDN procedures, results in greater efficacy. The Vessix V2 Renal
Denervation System may offer advantages since it allows for both longitudinal and
circumferential denervations with short treatment duration.
TCT-11
Renal Sympathetic Denervation - Inducing An Instantaneous And Persisting
24h Ambulatory Blood Pressure Drop In Patients With Resistant
Hypertension – Results From The Halle-RDN-Registry
Alexander Plehn1, Sebastian Dietz1, Konstantin Heinroth1, Henning Lemm1,
Maria Leuthold1, Silke Markau1, Uwe Raaz2, Therese Schubert1, Alexander Vogt1,
Karl Werdan1
1Martin Luther University Halle-Wittenberg, Halle, Germany, 2Stanford School of
Medicine, Stanford, CA
Background: Catheter-based renal sympathetic denervation (RDN) has proved to
significantly reduce blood pressure (BP) in patients with resistant hypertension. So far,
current available data are almost entirely derived from office-based blood pressure
measurements (OBPM) with only few data relying on 24h ambulatory blood pressure
monitoring (ABPM). However, ABPM is commonly regarded as a much more reliable
method and therefore a better approach to evaluate the effects of RDN.
Methods: Our study carefully investigated the early and subsequent blood pressure
response to RDN in a cohort of 120 consecutive patients with resistant hypertension
(systolic BP 150 mm Hg on 3 antihypertensive drugs). Baseline values included a
mean age of 64.59 years, 48% women, 45% diabetic, 18% coronary artery disease and
5.7 1.5 antihypertensive medications. A 24h Holter BP monitoring was recorded in
every patient 24h before as well as 24h, 3 and 6 months after RDN. BP readings were then
averaged according to daytime (7:00am-22:00pm), nighttime (22:00pm-7:00am) and 24
hours intervals. All data were statistically analysed with repeated measures ANOVA and
Greenhouse-Geisser correction if indicated.
Results: In treated patients mean averaged systolic 24h BP was reduced by 9.681.59
mmHg (p0.001; n 120) during the first 24 hours. Systolic blood pressure reduction
appeared to be much higher at daytime (12.11.63 mm HG; p0.001) compared to
nighttime (4.41.79 mm Hg; p0.016) which might indicate the role of sympathetic
activity at daytime. A concordant effect on diastolic BP was observed: 5.90.88 mmHg
(p0.001). Systolic BP reduction sustained at 3 (6.31.84 mm Hg, p0.005, n 74) and
6 months (6.73.0 mm Hg, p0,201, n 38) without further decrease.
Conclusions: In patients with resistant hypertension, catheter-based RDN results in an
immediate and persisting reduction of systolic and diastolic ABPM. Compared to
office-based data ABPM effects are expectedly less pronounced. Our analysis did not
confirm the so far described gradual drop in BP up to 6 months. On the contrary a slight
non-significant compensation of BP reduction was observed after the initial drop between
day one and the 3 as well as 6 months follow-ups.
TCT-12
Long-term Follow-up of Catheter-based Renal Denervation For Resistant
Hypertension Confirms Durable Blood Pressure Reduction
Henry Krum1, Markus Schlaich2, Paul Sobotka3, Murray Esler2, Felix Mahfoud4,
Michael Böhm4, Mark Dunlap5, Krishna Rocha-Singh6, Richard Katholi7
1Monash University and The Alfred Hospital, Melbourne, Australia, 2Baker IDI
Heart and Diabetes Institute, Melbourne, Australia, 3The Ohio State University,
Columbus, OH, 4Universitätsklinikum des Saarlandes, Homburg, Saarland,
5MetroHealth Heart and Vascular Center, Cleveland, OH, 6Prairie Heart Institute,
Springfield, IL, 7Prairie Heart Insitute, Springfield , IL
Background: Renal denervation (RDN) using low power radiofrequency energy has
been shown to substantially reduce blood pressure (BP) in patients with treatment-
resistant hypertension. Documentation of duration of antihypertensive effects and the
potential for late development of adverse events is important for determining proper
positioning of this therapy.
Methods: Symplicity HTN-1 is an open-label cohort study which enrolled 153 patients
with systolic BP 160 mm Hg while taking 3 antihypertensive drugs at optimal
dosages, including a diuretic. Patients were followed semi-annually to 3 years post-RDN.
Changes in office-based BP, changes in distribution of BP measurements, renal function,
electrolytes, and medication usage were monitored through 3 years follow-up. Systolic BP
(SBP) reductions of 10 mmHg or more were determined at 1 month and the rates of
delayed response thereafter were calculated.
Results: 114 patients have been followed through 2 years post-RDN and 34 patients for
3 years. Mean age at baseline was 5711 years; 39% of patients were female; 31% had
type 2 diabetes mellitus; eGFR was 8320 mL/min and BP was 175/9817/15 mmHg.
Mean SBP change post-RDN was 32.7  18.4 mmHg at 2 years and 33.1  13.3
mmHg at 3 years. A SBP drop 10 mmHg occurred in 69% of patients at 1 month, and
of the patients with10 mmHg drop in SBP at 1 month 64%, 82%, and 100% responded
with a reduction in SBP 10 mmHg at 1, 2, and 3 years, respectively. There was one
progression of a pre-existing renal artery stenosis and 3 deaths 2.0% unrelated to the
device or therapy.
Conclusions: RDN results in a significant and durable reduction of SBP in patients with
treatment-resistant hypertension. Patients with minimal initial reduction in BP may have
significant reductions later which are not explained by medication changes. Safety and
efficacy data on a larger cohort of patients with 2 and 3 year follow-up will be presented.
TCT-13
Renal resistive indices, urinary albumin excretion and renal function in
patients with resistant hypertension after catheter-based renal sympathetic
denervation
Felix Mahfoud1, Bodo Cremers1, Christian Ukena1, Henry Krum2, Paul Sobotka3,
Markus Schlaich4, Bruno Scheller5, Ulrich Laufs1, Michael Böhm1
1Universitätsklinikum des Saarlandes, Homburg, Saarland, 2N/A, Victoria,
Australia, 3The Ohio State University, Columbus, OH, 4Baker Heart and Diabetes
Institute, Melbourne, Australia, 5Universitätsklinikum des Saarlandes, Homburg,
Germany
Background: Increased renal resistive index (RRI) and urinary albumin excretion (UAE)
are markers of hypertensive end-organ damage. Increased sympathetic activity is a main
contributor to the pathophysiology. Catheter-based renal sympathetic denervation (RD)
offers a new interventional approach to reduce renal sympathetic activity and blood
pressure in resistant hypertension. The influence of RD on renal hemodynamics, renal
function, and UAE in patients with resistant hypertension has not been studied.
Methods: One hundred consecutive patients with resistant hypertension were included in
the study. 88 underwent interventional RD and 12 served as controls. Systolic, diastolic
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